Materiały źródłowe

• #1 Deep vein thrombosis (DVT) – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/deep-vein-thrombosis/diagnosis-treatment/drc-20352563

  There are three main goals to DVT treatment. […] DVT treatment options include: […] Blood thinners. These medicines, also called anticoagulants, help prevent blood clots from getting bigger. Blood thinners reduce the risk of developing more clots. […] Clot busters (thrombolytics). These drugs are used for more-serious types of DVT or PE, or if other medications aren’t working. […] Filters. If you can’t take medicines to thin your blood, a filter may be placed into a large vein the vena cava in your belly (abdomen). A vena cava filter prevents clots that break loose from lodging in the lungs. […] Support stockings (compression stockings). These special knee socks help prevent blood from pooling in the legs. They help reduce leg swelling. Wear them on your legs from your feet to about the level of your knees. For DVT, you typically wear these stockings during the day for a few years, if possible.

• #2 Deep Vein Thrombosis (DVT)

  https://my.clevelandclinic.org/health/diseases/16911-deep-vein-thrombosis-dvt

  Deep vein thrombosis is a blood clot in a vein located deep within your body, usually in your leg. Get treatment right away so you can prevent serious complications. Treatments include medicines, compression stockings and surgery. Be patient. You may need to take medicine for a few months and wear compression stockings for two years. […] Treatments include medications called anticoagulants (blood thinners), compression stockings and elevating your affected leg(s) at different times throughout the day. In a minority of cases, when the DVT is extensive, invasive treatments (catheter-based procedures) may be required. […] The main goals of treatment are to: Keep the clot from getting bigger and involving other veins. Prevent the clot from breaking off in your vein and moving to your lungs. Lessen the risk of another blood clot. Prevent long-term complications from the blood clot (like chronic venous insufficiency).

• #3 Deep Vein Thrombosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK507708/

  A deep-vein thrombosis (DVT) is a blood clot that forms within the deep veins, usually of the leg, but can occur in the arms and the mesenteric and cerebral veins. […] This activity reviews the etiology, presentation, evaluation, and management of deep vein thrombosis and reviews the role of the interprofessional team in evaluating, diagnosing, and managing the condition. […] Summarize the treatment and management strategies for deep vein thrombosis, including preventative measures. […] Treatment of DVT aims to prevent pulmonary embolism, reduce morbidity, and prevent or minimize the risk of developing post-thrombotic syndrome. The cornerstone of treatment is anticoagulation. […] Treatment for DVT should be addressed mainly according to the underlying causality of DVT as follows: […] The preferred anticoagulant to address DVT in cancer-associated thromboembolism is low molecular weight heparin and factor Xa inhibitors, including rivaroxaban.

• #4 Deep Venous Thrombosis (DVT) Treatment & Management: Approach Considerations, General Principles of Anticoagulation, Heparin Use in Deep Venous Thrombosis

  https://emedicine.medscape.com/article/1911303-treatment

  The primary objectives for the treatment of deep venous thrombosis (DVT) are to prevent pulmonary embolism (PE), reduce morbidity, and prevent or minimize the risk of developing the postthrombotic syndrome (PTS). […] The mainstay of medical therapy for DVT has been anticoagulation since the introduction of heparin in the 1930s. Other anticoagulation drugs have subsequently been added to the treatment armamentarium over the years, such as vitamin K antagonists (VKA) (ie, warfarin) and low-molecular-weight heparin (LMWH). […] The immediate symptoms of DVT often resolve with anticoagulation alone, and the rationale for intervention is often the reduction of the long-term risk of PTS by 75%. […] Anticoagulant therapy is recommended for 3-12 months depending on the site of thrombosis and on the ongoing presence of risk factors.

• #5 Deep Venous Thrombosis (DVT) Treatment & Management: Approach Considerations, General Principles of Anticoagulation, Heparin Use in Deep Venous Thrombosis

  https://emedicine.medscape.com/article/1911303-treatment

  If DVT recurs, if a chronic hypercoagulability is identified, or if the PE is life-threatening, lifetime anticoagulation therapy may be recommended. […] Anticoagulant therapy remains the mainstay of medical therapy for deep venous thrombosis (DVT) because it is noninvasive, it treats most patients (approximately 90%) with no immediate demonstrable physical sequelae of DVT, it has a low risk of complications, and its outcome data demonstrate an improvement in morbidity and mortality. […] First-line therapy for non-high risk venous thromboembolism (VTE) or pulmonary embolism (PE) consists of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, or edoxaban) over vitamin K antagonists (VKAs). […] Inferior vena cava filters are not recommended in patients with acute VTE on anticoagulant therapy.

• #6 Diagnosis and treatment of deep-vein thrombosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC1609160/

  Deep-vein thrombosis (DVT) is a common condition that can lead to complications such as postphlebitic syndrome, pulmonary embolism and death. […] The mainstay of treatment of DVT is anticoagulation therapy, whereas interventions such as thrombolysis and placement of inferior vena cava filters are reserved for special situations. […] The use of low-molecular-weight heparin allows for outpatient management of most patients with DVT. […] Initial therapy must involve therapeutic doses of either unfractionated heparin or LMW heparin. Initial treatment with oral anticoagulant therapy alone is unacceptable. […] The ease of administration and efficacy of LMW heparin make this the preferred anticoagulant, whether given on an outpatient or an inpatient basis. […] Early studies evaluating the outpatient treatment of patients with DVT determined that this practice is safe and effective in selected patients.

• #7 Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy | AAFP

  https://www.aafp.org/pubs/afp/issues/2017/0301/p295.html

  Anticoagulation is the mainstay of VTE treatment. Most patients with deep venous thrombosis or low-risk pulmonary embolism can be treated in the outpatient setting with low-molecular-weight heparin and a vitamin K antagonist (warfarin) or direct-acting oral anticoagulants. […] Inpatient treatment of VTE begins with parenteral agents, preferably low-molecular-weight heparin. Unfractionated heparin is used if a patient is hemodynamically unstable or has severe renal insufficiency, high bleeding risk, hemodynamic instability, or morbid obesity. […] Current guidelines recommend anticoagulation for a minimum of three months. Special situations, such as active cancer and pregnancy, require long-term use of low-molecular-weight or unfractionated heparin. […] Anticoagulation beyond three months should be individualized based on a risk/benefit analysis.

• #8 Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy | AAFP

  https://www.aafp.org/pubs/afp/issues/2017/0301/p295.html

  Guidelines recommend low-molecular-weight over unfractionated heparin, which is supported by multiple therapeutic trials showing greater effectiveness and safety and lower mortality. […] The ACCP recommends the use of direct-acting anticoagulants over warfarin for VTE treatment in patients without cancer (weak recommendation based on moderate quality evidence, per the ACCP grading system). […] For patients with recurrent VTE who are already taking an oral anticoagulant, low-molecular-weight heparin is recommended over other oral anticoagulants. […] For patients with recurrent VTE while taking a low-molecular-weight heparin, the dose should be increased by 25% to 33% (weak recommendations based on moderate to poor quality evidence per the ACCP grading system). […] If there is an absolute contraindication to therapeutic anticoagulation, complications from anticoagulation, or failure of anticoagulation in a patient with acute proximal DVT, an inferior vena cava filter may be indicated. […] Long-term anticoagulation reduces the risk of recurrent VTE but results in more bleeding events. Considering this trade-off, it is critical that the duration of anticoagulation therapy be individualized based on the patient’s risk of recurrence vs. risk of bleeding.

• #9 Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy | AAFP

  https://www.aafp.org/pubs/afp/issues/2017/0301/p295.html

  Guidelines recommend low-molecular-weight over unfractionated heparin, which is supported by multiple therapeutic trials showing greater effectiveness and safety and lower mortality. […] The ACCP recommends the use of direct-acting anticoagulants over warfarin for VTE treatment in patients without cancer (weak recommendation based on moderate quality evidence, per the ACCP grading system). […] For patients with recurrent VTE who are already taking an oral anticoagulant, low-molecular-weight heparin is recommended over other oral anticoagulants. […] For patients with recurrent VTE while taking a low-molecular-weight heparin, the dose should be increased by 25% to 33% (weak recommendations based on moderate to poor quality evidence per the ACCP grading system). […] If there is an absolute contraindication to therapeutic anticoagulation, complications from anticoagulation, or failure of anticoagulation in a patient with acute proximal DVT, an inferior vena cava filter may be indicated. […] Long-term anticoagulation reduces the risk of recurrent VTE but results in more bleeding events. Considering this trade-off, it is critical that the duration of anticoagulation therapy be individualized based on the patient’s risk of recurrence vs. risk of bleeding.

• #10 Diagnosis and treatment of deep-vein thrombosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC1609160/

  Deep-vein thrombosis (DVT) is a common condition that can lead to complications such as postphlebitic syndrome, pulmonary embolism and death. […] The mainstay of treatment of DVT is anticoagulation therapy, whereas interventions such as thrombolysis and placement of inferior vena cava filters are reserved for special situations. […] The use of low-molecular-weight heparin allows for outpatient management of most patients with DVT. […] Initial therapy must involve therapeutic doses of either unfractionated heparin or LMW heparin. Initial treatment with oral anticoagulant therapy alone is unacceptable. […] The ease of administration and efficacy of LMW heparin make this the preferred anticoagulant, whether given on an outpatient or an inpatient basis. […] Early studies evaluating the outpatient treatment of patients with DVT determined that this practice is safe and effective in selected patients.

• #11 Deep Vein Thrombosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK507708/

  In circumstances where once-daily oral therapy is the preferred management, the following options are viable; 1. rivaroxaban, 2. edoxaban, and 3. vitamin-K antagonist (VKA). […] Moreover, the following guidelines address the required duration of treatment. […] Prescribe low-molecular-weight heparin or fondaparinux for 5 days or until the international normalized ratio (INR) is greater than 2 for 24 hours (unfractionated heparin for patients with renal failure and increased risk of bleeding). […] If thrombolytic therapy is indicated, unfractionated heparin is indicated. […] The use of thrombolytic therapy can result in an intracranial bleed, and hence, careful patient selection is vital. […] Compression hosiery: Below-knee graduated compression stockings with an ankle pressure greater than 23 mm Hg for 2 years if there are no contraindications.

• #12 Anticoagulation in Deep Venous Thrombosis: Advantages of Anticoagulant Therapy, Initial Anticoagulation Therapy, Long-Term Anticoagulation

  https://emedicine.medscape.com/article/1926110-overview

  The American Society of Hematology (ASH) released their updated recommendations on the management of venous thromboembolism (VTE) (deep vein thrombosis [DVT] and pulmonary embolism [PE]) in October 2020. […] For patients with PE and hemodynamic compromise, it is recommended that thrombolytic therapy followed by anticoagulation be used over anticoagulation alone. […] For patients with DVT and/or PE who have completed primary treatment and will continue vitamin K antagonist (VKA) therapy as secondary prevention, it is recommended that an international normalized ratio (INR) range of 2.0 to 3.0 be used over a lower INR range (eg, 1.5-1.9). […] For patients with a recurrent unprovoked DVT and/or PE, indefinite antithrombotic therapy is recommended over stopping anticoagulation after completion of primary treatment.

• #13 Diagnosis and treatment of deep-vein thrombosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC1609160/

  For the majority of patients with DVT, oral therapy with vitamin K antagonists (e.g., warfarin) is very effective for long-term prevention of recurrent thrombosis. […] The risk can be classified into the following 5 categories: First proximal DVT occurs in the context of a transient risk factor (e.g., surgery or trauma). […] After a second recurrence of DVT, the risk of further thromboembolic events following the discontinuation of anticoagulation therapy is felt to be excessive if only 6 months of oral anticoagulation therapy is administered. […] The standard intensity of oral anticoagulation therapy is an international normalized ratio (INR) of 2 to 3. […] Although anticoagulation therapy is the mainstay of treatment of DVT, thrombolysis and placement of an inferior vena cava filter are 2 interventions that deserve mention. […] LMW heparin is the treatment of choice for DVT during pregnancy.

• #14 Deep Vein Thrombosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK507708/

  Inferior vena cava filters: If anticoagulation is contraindicated or if emboli are occurring despite adequate anticoagulation. […] Rivaroxaban, apixaban, dabigatran, edoxaban, and betrixaban are relatively newer factor Xa inhibitors approved for prophylaxis of deep vein thrombosis. […] Inferior vena cava filters are not recommended in acute DVT. […] For patients with catheter-associated thrombosis, treatment consists of removing the catheter or anticoagulation if the catheter remains.

• #15 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  Use of direct oral anticoagulants (DOACs) are recommended as first-line treatment of acute DVT or PE. DOAC therapy is preferred over vitamin K antagonists (VKAs) for most patients without severe renal insufficiency (creatinine clearance). […] For most patients with proximal DVT, the ASH guidelines suggest anticoagulation therapy alone over thrombolytic therapy. Thrombolysis is reasonable to consider in patients presenting with limb-threatening DVT (phlegmasia cerulea dolens) or for select younger patients at low bleeding risk with iliofemoral DVT. […] For patients with acute PE and evidence of right ventricular dysfunction (by echocardiography and/or biomarkers), the ASH guidelines suggest anticoagulation alone over routine use of thrombolysis. Thrombolysis is reasonable to consider for patients at low bleeding risk who are at high risk for decompensation.

• #16 Deep Vein Thrombosis (DVT) Treatment: Medications, Procedures & Home Care

  https://www.webmd.com/dvt/deep-vein-thrombosis-treatment-dvt

  Anticoagulants are the most common DVT treatment. Your doctor may want you to take them for three months or more. […] You may start anticoagulants through an IV (in your vein) or injection. […] Your doctor can also give you heparin as a shot. […] You may also take warfarin (Coumadin and Jantoven) after a few days. […] If heparin and warfarin treatments don’t work for you, you might get another treatment. These are sometimes called direct oral anticoagulants (DOACs). […] Your doctor may suggest a clot-busting medicine. They are called thrombolytic agents. […] This treatment quickly breaks up your clot and restores blood flow to the area. […] When taking blood thinners or clot-busting isn’t possible, your doctor may want to try a more involved procedure. […] An IVC filter traps blood clots before they cause a pulmonary embolism (clot in your lung).

• #17 Medications for Deep Venous Thrombosis – Cardiovascular Disorders – MSD Manual Professional Edition

  https://www.msdmanuals.com/professional/cardiovascular-disorders/peripheral-venous-disorders/medications-for-deep-venous-thrombosis

  Rivaroxaban and apixaban can be started as monotherapy immediately upon diagnosis or used in transition from an injectable heparin at any time without overlap. […] Dabigatran 150 mg orally twice a day is given only after an initial 5 days of treatment with LMWH. […] Warfarin is a treatment option for patients with DVT who are not pregnant. […] Thrombolytic agents, which include alteplase, tenecteplase, and streptokinase, lyse clots and may be more effective than heparin alone in selected patients with DVT, but the risk of bleeding is higher than with heparin alone. […] For patients with DVT, a clinical trial showed that catheter-directed thrombolytic therapy did not reduce the incidence of post-thrombotic syndrome compared with conventional anticoagulant therapy. […] Consequently, thrombolytic agents should be considered only in highly selected patients with DVT.

• #18 Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy | AAFP

  https://www.aafp.org/pubs/afp/issues/2017/0301/p295.html

  Guidelines recommend low-molecular-weight over unfractionated heparin, which is supported by multiple therapeutic trials showing greater effectiveness and safety and lower mortality. […] The ACCP recommends the use of direct-acting anticoagulants over warfarin for VTE treatment in patients without cancer (weak recommendation based on moderate quality evidence, per the ACCP grading system). […] For patients with recurrent VTE who are already taking an oral anticoagulant, low-molecular-weight heparin is recommended over other oral anticoagulants. […] For patients with recurrent VTE while taking a low-molecular-weight heparin, the dose should be increased by 25% to 33% (weak recommendations based on moderate to poor quality evidence per the ACCP grading system). […] If there is an absolute contraindication to therapeutic anticoagulation, complications from anticoagulation, or failure of anticoagulation in a patient with acute proximal DVT, an inferior vena cava filter may be indicated. […] Long-term anticoagulation reduces the risk of recurrent VTE but results in more bleeding events. Considering this trade-off, it is critical that the duration of anticoagulation therapy be individualized based on the patient’s risk of recurrence vs. risk of bleeding.

• #19 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  Use of direct oral anticoagulants (DOACs) are recommended as first-line treatment of acute DVT or PE. DOAC therapy is preferred over vitamin K antagonists (VKAs) for most patients without severe renal insufficiency (creatinine clearance). […] For most patients with proximal DVT, the ASH guidelines suggest anticoagulation therapy alone over thrombolytic therapy. Thrombolysis is reasonable to consider in patients presenting with limb-threatening DVT (phlegmasia cerulea dolens) or for select younger patients at low bleeding risk with iliofemoral DVT. […] For patients with acute PE and evidence of right ventricular dysfunction (by echocardiography and/or biomarkers), the ASH guidelines suggest anticoagulation alone over routine use of thrombolysis. Thrombolysis is reasonable to consider for patients at low bleeding risk who are at high risk for decompensation.

• #20 Management of lower-extremity venous thromboembolism: An updated review | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/91/4/229

  The 2021 CHEST guidelines recommend treating proximal DVT with anticoagulation for at least 3 months. […] Proximal DVT confers up to a 50% risk of pulmonary embolism if left untreated, so treatment with anticoagulation is recommended even in the absence of symptoms (incidental DVT). […] The 2021 CHEST guidelines recommend the use of DOACs over warfarin whenever possible, based on data showing a lower risk of major bleeding (especially intracranial hemorrhage) with DOACs vs warfarin. […] The 2021 CHEST guidelines recommend fondaparinux as the agent of choice for the treatment of SVT, but rivaroxaban is an acceptable alternative. […] When anticoagulation is indicated in patients with DVT, treatment should continue for at least 3 months after the initial thrombotic episode. […] Anticoagulation beyond 3 months, without a specific end date, is recommended for patients at particularly high risk of recurrence.

• #21 Patient education: Deep vein thrombosis (DVT) (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/deep-vein-thrombosis-dvt-beyond-the-basics

  Duration of treatment—Anticoagulation is recommended for a minimum of three months in a patient with DVT. […] Most experts recommend continuing anticoagulation indefinitely for people with two or more episodes of venous thrombosis or if a risk factor for clotting persists (eg, antiphospholipid syndrome, cancer). […] Walking during deep vein thrombosis treatment—Once an anticoagulant has been started and symptoms (such as pain and swelling) are under control, you are strongly encouraged to get up and walk around periodically. Studies show that there is no increased risk of complications (eg, pulmonary embolus) in people who get up and walk, and walking may in fact help you feel better faster. […] Thrombolytic therapy—In some severe life-threatening cases, a health care provider will recommend an intravenous medicine to dissolve blood clots (ie, a „clot-busting” medication). This is called thrombolytic therapy. This therapy is reserved for people who have serious complications related to DVT or PE and who have a low risk of serious bleeding as a side effect of the therapy.

• #22 Medications for Deep Venous Thrombosis – Cardiovascular Disorders – MSD Manual Professional Edition

  https://www.msdmanuals.com/professional/cardiovascular-disorders/peripheral-venous-disorders/medications-for-deep-venous-thrombosis

  The main disadvantage is the higher cost compared to warfarin and the high cost of DOAC reversal agents in the case of bleeding or need for an urgent surgery or procedure. […] Duration of treatment varies. Patients with transient risk factors for DVT can usually stop taking anticoagulants after 3 to 6 months. Patients with idiopathic DVT with no known risk factors, or recurrent DVT should take anticoagulants for at least 6 months and, in selected patients, probably for life unless they are at high risk for bleeding complications. […] A low molecular weight heparin is one of the initial treatments of choice because LMWHs can be given on an outpatient basis. […] LMWHs and direct oral anticoagulants are first-line treatment options for patients with cancer-associated DVT. […] Unfractionated heparin may be used instead of LMWH for patients who are hospitalized and for patients who have renal insufficiency or failure.

• #23 Diagnosis and treatment of deep-vein thrombosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC1609160/

  For the majority of patients with DVT, oral therapy with vitamin K antagonists (e.g., warfarin) is very effective for long-term prevention of recurrent thrombosis. […] The risk can be classified into the following 5 categories: First proximal DVT occurs in the context of a transient risk factor (e.g., surgery or trauma). […] After a second recurrence of DVT, the risk of further thromboembolic events following the discontinuation of anticoagulation therapy is felt to be excessive if only 6 months of oral anticoagulation therapy is administered. […] The standard intensity of oral anticoagulation therapy is an international normalized ratio (INR) of 2 to 3. […] Although anticoagulation therapy is the mainstay of treatment of DVT, thrombolysis and placement of an inferior vena cava filter are 2 interventions that deserve mention. […] LMW heparin is the treatment of choice for DVT during pregnancy.

• #24 Deep vein thrombosis – Symptoms, diagnosis and treatment | BMJ Best Practice

  https://bestpractice.bmj.com/topics/en-gb/3000112

  Deep vein thrombosis (DVT) is the development of a blood clot within a vein deep to the muscular tissue planes. […] DVT is usually treated with anticoagulants such as unfractionated heparin, low molecular weight heparin, fondaparinux, rivaroxaban, apixaban, edoxaban, dabigatran, and/or warfarin. Interventional therapies, including thrombolysis, are rarely indicated. […] Generally, anticoagulant therapy for at least 3 months is required for patients with DVT. Thereafter, continued anticoagulant therapy for secondary prevention is indicated in selected patients to reduce the risk of recurrent events.

• #25 Deep vein thrombosis (DVT) – symptoms, signs and treatment | healthdirect

  https://www.healthdirect.gov.au/deep-vein-thrombosis

  See your doctor immediately if you have signs of a deep vein thrombosis (red, swollen leg). Call triple zero (000) and ask for an ambulance if you have chest pain, trouble breathing or symptoms of stroke or heart attack. […] The exact treatment for DVT depends on the location of the clot and your risk of complications. If you have DVT, you will probably be treated with an anticoagulant (blood thinner) medicine. This will reduce further blood clotting. […] You might take tablets or have injections. You may need to take anticoagulant medicine for several months, or even longer. […] You may also need to wear compression stockings. […] In rare cases, you may need a different type of medicine called a thrombolytic. This is used to dissolve and break down the blood clot.

• #26 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  For patients with extensive DVT in whom thrombolysis is considered appropriate, the ASH guidelines suggest using catheter-directed thrombolysis over systemic thrombolysis. In contrast, for patients with acute PE in whom thrombolysis is considered appropriate, the ASH guidelines suggest using systemic thrombolysis over catheter-directed thrombolysis partially due to a paucity of randomized trial data. […] For patients with proximal DVT and significant pre-existing cardiopulmonary disease as well as patients with PE and hemodynamic compromise, the ASH guidelines suggest anticoagulation alone over anticoagulation plus inferior vena cava (IVC) filter placement. The use of retrievable IVC filters is appropriate for patients with a contraindication to anticoagulation. […] The ASH guidelines define the treatment period of acute DVT/PE as initial management (first 5-21 days), primary treatment (first 3-6 months), and secondary prevention (beyond the first 3-6 months). The guidelines favor shorter courses of anticoagulation (3-6 months) for acute DVT/PE associated with a transient risk factor. The guidelines suggest indefinite anticoagulation for most patients with unprovoked DVT/PE or a DVT/PE associated with a chronic risk factor.

• #27 Diagnosis and treatment of deep-vein thrombosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC1609160/

  For the majority of patients with DVT, oral therapy with vitamin K antagonists (e.g., warfarin) is very effective for long-term prevention of recurrent thrombosis. […] The risk can be classified into the following 5 categories: First proximal DVT occurs in the context of a transient risk factor (e.g., surgery or trauma). […] After a second recurrence of DVT, the risk of further thromboembolic events following the discontinuation of anticoagulation therapy is felt to be excessive if only 6 months of oral anticoagulation therapy is administered. […] The standard intensity of oral anticoagulation therapy is an international normalized ratio (INR) of 2 to 3. […] Although anticoagulation therapy is the mainstay of treatment of DVT, thrombolysis and placement of an inferior vena cava filter are 2 interventions that deserve mention. […] LMW heparin is the treatment of choice for DVT during pregnancy.

• #28 Patient education: Deep vein thrombosis (DVT) (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/deep-vein-thrombosis-dvt-beyond-the-basics

  Duration of treatment—Anticoagulation is recommended for a minimum of three months in a patient with DVT. […] Most experts recommend continuing anticoagulation indefinitely for people with two or more episodes of venous thrombosis or if a risk factor for clotting persists (eg, antiphospholipid syndrome, cancer). […] Walking during deep vein thrombosis treatment—Once an anticoagulant has been started and symptoms (such as pain and swelling) are under control, you are strongly encouraged to get up and walk around periodically. Studies show that there is no increased risk of complications (eg, pulmonary embolus) in people who get up and walk, and walking may in fact help you feel better faster. […] Thrombolytic therapy—In some severe life-threatening cases, a health care provider will recommend an intravenous medicine to dissolve blood clots (ie, a „clot-busting” medication). This is called thrombolytic therapy. This therapy is reserved for people who have serious complications related to DVT or PE and who have a low risk of serious bleeding as a side effect of the therapy.

• #29 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  For patients with extensive DVT in whom thrombolysis is considered appropriate, the ASH guidelines suggest using catheter-directed thrombolysis over systemic thrombolysis. In contrast, for patients with acute PE in whom thrombolysis is considered appropriate, the ASH guidelines suggest using systemic thrombolysis over catheter-directed thrombolysis partially due to a paucity of randomized trial data. […] For patients with proximal DVT and significant pre-existing cardiopulmonary disease as well as patients with PE and hemodynamic compromise, the ASH guidelines suggest anticoagulation alone over anticoagulation plus inferior vena cava (IVC) filter placement. The use of retrievable IVC filters is appropriate for patients with a contraindication to anticoagulation. […] The ASH guidelines define the treatment period of acute DVT/PE as initial management (first 5-21 days), primary treatment (first 3-6 months), and secondary prevention (beyond the first 3-6 months). The guidelines favor shorter courses of anticoagulation (3-6 months) for acute DVT/PE associated with a transient risk factor. The guidelines suggest indefinite anticoagulation for most patients with unprovoked DVT/PE or a DVT/PE associated with a chronic risk factor.

• #30 Diagnosis and treatment of deep-vein thrombosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC1609160/

  For the majority of patients with DVT, oral therapy with vitamin K antagonists (e.g., warfarin) is very effective for long-term prevention of recurrent thrombosis. […] The risk can be classified into the following 5 categories: First proximal DVT occurs in the context of a transient risk factor (e.g., surgery or trauma). […] After a second recurrence of DVT, the risk of further thromboembolic events following the discontinuation of anticoagulation therapy is felt to be excessive if only 6 months of oral anticoagulation therapy is administered. […] The standard intensity of oral anticoagulation therapy is an international normalized ratio (INR) of 2 to 3. […] Although anticoagulation therapy is the mainstay of treatment of DVT, thrombolysis and placement of an inferior vena cava filter are 2 interventions that deserve mention. […] LMW heparin is the treatment of choice for DVT during pregnancy.

• #31 Deep Vein Thrombosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK507708/

  A deep-vein thrombosis (DVT) is a blood clot that forms within the deep veins, usually of the leg, but can occur in the arms and the mesenteric and cerebral veins. […] This activity reviews the etiology, presentation, evaluation, and management of deep vein thrombosis and reviews the role of the interprofessional team in evaluating, diagnosing, and managing the condition. […] Summarize the treatment and management strategies for deep vein thrombosis, including preventative measures. […] Treatment of DVT aims to prevent pulmonary embolism, reduce morbidity, and prevent or minimize the risk of developing post-thrombotic syndrome. The cornerstone of treatment is anticoagulation. […] Treatment for DVT should be addressed mainly according to the underlying causality of DVT as follows: […] The preferred anticoagulant to address DVT in cancer-associated thromboembolism is low molecular weight heparin and factor Xa inhibitors, including rivaroxaban.

• #32 Deep vein thrombosis – Knowledge @ AMBOSS

  https://www.amboss.com/us/knowledge/deep-vein-thrombosis/

  Primary prevention of VTE is recommended in patients at risk of DVT or PE (e.g., seriously ill medical patients, most surgical patients, and long-distance travelers with additional risk factors for VTE) and includes mechanical and pharmacological measures. […] Anticoagulation therapy in UEDVT: Initiate parenteral anticoagulation using unfractionated heparin or low molecular weight heparin (LMWH). […] Continue long-term anticoagulation for at least 3 months with LMWH, vitamin K antagonists, or direct oral anticoagulants. […] Initial parenteral anticoagulation (with LMWH, fondaparinux, or UFH) should be initiated at the same time as warfarin and before dabigatran and edoxaban. Initial parenteral anticoagulation is not required for patients receiving rivaroxaban or apixaban. […] The decision to extend anticoagulation indefinitely after primary treatment is typically made after balancing the risk of recurrent DVT (e.g., for patients with chronic risk factors) with the bleeding risk on anticoagulation for VTE. […] Patients with active cancer and VTE should receive anticoagulation for at least 6 months. […] Avoid warfarin and DOACs in pregnancy.

• #33 Deep vein thrombosis (DVT) – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/deep-vein-thrombosis/diagnosis-treatment/drc-20352563

  There are three main goals to DVT treatment. […] DVT treatment options include: […] Blood thinners. These medicines, also called anticoagulants, help prevent blood clots from getting bigger. Blood thinners reduce the risk of developing more clots. […] Clot busters (thrombolytics). These drugs are used for more-serious types of DVT or PE, or if other medications aren’t working. […] Filters. If you can’t take medicines to thin your blood, a filter may be placed into a large vein the vena cava in your belly (abdomen). A vena cava filter prevents clots that break loose from lodging in the lungs. […] Support stockings (compression stockings). These special knee socks help prevent blood from pooling in the legs. They help reduce leg swelling. Wear them on your legs from your feet to about the level of your knees. For DVT, you typically wear these stockings during the day for a few years, if possible.

• #34 Deep Vein Thrombosis (DVT) Treatment: Medications, Procedures & Home Care

  https://www.webmd.com/dvt/deep-vein-thrombosis-treatment-dvt

  Anticoagulants are the most common DVT treatment. Your doctor may want you to take them for three months or more. […] You may start anticoagulants through an IV (in your vein) or injection. […] Your doctor can also give you heparin as a shot. […] You may also take warfarin (Coumadin and Jantoven) after a few days. […] If heparin and warfarin treatments don’t work for you, you might get another treatment. These are sometimes called direct oral anticoagulants (DOACs). […] Your doctor may suggest a clot-busting medicine. They are called thrombolytic agents. […] This treatment quickly breaks up your clot and restores blood flow to the area. […] When taking blood thinners or clot-busting isn’t possible, your doctor may want to try a more involved procedure. […] An IVC filter traps blood clots before they cause a pulmonary embolism (clot in your lung).

• #35 Deep Vein Thrombosis (DVT) | Inova

  https://www.inova.org/our-services/inova-schar-heart-and-vascular/conditions-treatments/deep-vein-thrombosis-dvt

  Deep vein thrombosis (DVT) is a serious condition in which a thrombus, or blood clot, develops within a deep vein, usually in a leg. […] Because of its life-threatening nature, it is imperative to diagnose and treat acute deep vein thrombosis quickly. Anticoagulation medication (referred to as „blood thinners”) is the most common and effective treatment for DVT. However, advanced cases may require thrombolytic therapy or inferior vena cava (IVC) filters. […] Anticoagulants are often referred to as „blood thinners,” although they don’t actually thin the blood. While these drugs do not dissolve the clot, they can stabilize it by allowing the clot to stick to the vein wall, thereby avoiding pulmonary embolism and allowing the body to eliminate or partially dissolve the clot over time. […] Rarely, the symptoms of deep vein thrombosis or pulmonary embolism are so severe that more aggressive treatment is needed. Medications that rapidly dissolve blood clots, called thrombolytics, are used selectively in individual patients in severe cases of DVT or PE.

• #36 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  Use of direct oral anticoagulants (DOACs) are recommended as first-line treatment of acute DVT or PE. DOAC therapy is preferred over vitamin K antagonists (VKAs) for most patients without severe renal insufficiency (creatinine clearance). […] For most patients with proximal DVT, the ASH guidelines suggest anticoagulation therapy alone over thrombolytic therapy. Thrombolysis is reasonable to consider in patients presenting with limb-threatening DVT (phlegmasia cerulea dolens) or for select younger patients at low bleeding risk with iliofemoral DVT. […] For patients with acute PE and evidence of right ventricular dysfunction (by echocardiography and/or biomarkers), the ASH guidelines suggest anticoagulation alone over routine use of thrombolysis. Thrombolysis is reasonable to consider for patients at low bleeding risk who are at high risk for decompensation.

• #37 Patient education: Deep vein thrombosis (DVT) (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/deep-vein-thrombosis-dvt-beyond-the-basics

  Duration of treatment—Anticoagulation is recommended for a minimum of three months in a patient with DVT. […] Most experts recommend continuing anticoagulation indefinitely for people with two or more episodes of venous thrombosis or if a risk factor for clotting persists (eg, antiphospholipid syndrome, cancer). […] Walking during deep vein thrombosis treatment—Once an anticoagulant has been started and symptoms (such as pain and swelling) are under control, you are strongly encouraged to get up and walk around periodically. Studies show that there is no increased risk of complications (eg, pulmonary embolus) in people who get up and walk, and walking may in fact help you feel better faster. […] Thrombolytic therapy—In some severe life-threatening cases, a health care provider will recommend an intravenous medicine to dissolve blood clots (ie, a „clot-busting” medication). This is called thrombolytic therapy. This therapy is reserved for people who have serious complications related to DVT or PE and who have a low risk of serious bleeding as a side effect of the therapy.

• #38 Deep Vein Thrombosis (DVT) Treatment Treatment – NYC & Westchester | ColumbiaDoctors – New York | ColumbiaDoctors

  https://www.columbiadoctors.org/specialties/radiology/our-services/interventional-radiology/deep-vein-thrombosis-dvt-treatment

  Using image guidance and minimally-invasive tools, Columbia’s interventional radiologists perform thousands of procedures each year to treat deep vein thrombosis (DVT) and many other conditions that would otherwise require open surgery. […] DVT is most often treated with blood thinners and other medications. For patients with more serious clots, or when medications aren’t working or can’t be taken, interventional radiologists use a variety of techniques to break up and dissolve new clots, or re-open veins that have longstanding blockages: […] Thrombolysis and thrombectomy are procedures used to break up and dissolve acute (new) blood clots. […] Thrombolysis is a minimally invasive procedure in which we administer clot-dissolving drugs directly into the clot to break it up. During thrombectomy we use a catheter tipped with a tool that mechanically breaks up the clot.

• #39 Deep Vein Thrombosis (DVT) Treatment Treatment – NYC & Westchester | ColumbiaDoctors – New York | ColumbiaDoctors

  https://www.columbiadoctors.org/specialties/radiology/our-services/interventional-radiology/deep-vein-thrombosis-dvt-treatment

  These two procedures are sometimes used together, and are useful for very large clots or in people who are at high risk of developing a pulmonary embolism. […] The most common complications of thrombolysis and thrombectomy include bleeding from the needle puncture. Other complications include low blood pressure, an allergic reaction to the clot-busting medication, post-thrombotic syndrome (swelling, pain, and ulcers (sores), or, very rarely, Intracranial hemorrhage (bleeding in the brain tissue). […] After the procedure we will have you rest in the recovery area, and we will give you intravenous fluids, antibiotics to prevent infection, and painkillers to relieve discomfort at the catheter insertion site.

• #40 Effective DVT Treatment of Thrombectomy & Thrombolysis

  https://drakhilmonga.com/blog/effective-treatment-thrombectomy-and-thrombolysis/

  Thrombectomy is a minimally invasive procedure designed to remove blood clots from the blood vessels. It is typically performed in cases where the clot is large and causing significant obstruction or when the patient does not respond well to medication. This method involves inserting a catheter into the impacted vein, often through a small incision in the groin. The catheter is guided to the clot, where it either mechanically breaks up the clot or uses suction to remove it. […] Thrombolysis involves using drugs, known as thrombolytic agents, to dissolve blood clots. It is a less invasive option compared to thrombectomy and is often used for smaller clots. Thrombolysis can be administered in two ways: […] Pharmacomechanical thrombectomy is a minimally invasive procedure combining thrombectomy and thrombolysis to treat Deep Vein Thrombosis (DVT) without surgery. A catheter is inserted into the vein to mechanically break up the clot while delivering thrombolytic drugs directly to dissolve it. This method is effective for large clots, providing immediate relief with minimal surgical risks like infection or bleeding.

• #41 Medications for Deep Venous Thrombosis – Cardiovascular Disorders – MSD Manual Professional Edition

  https://www.msdmanuals.com/professional/cardiovascular-disorders/peripheral-venous-disorders/medications-for-deep-venous-thrombosis

  Rivaroxaban and apixaban can be started as monotherapy immediately upon diagnosis or used in transition from an injectable heparin at any time without overlap. […] Dabigatran 150 mg orally twice a day is given only after an initial 5 days of treatment with LMWH. […] Warfarin is a treatment option for patients with DVT who are not pregnant. […] Thrombolytic agents, which include alteplase, tenecteplase, and streptokinase, lyse clots and may be more effective than heparin alone in selected patients with DVT, but the risk of bleeding is higher than with heparin alone. […] For patients with DVT, a clinical trial showed that catheter-directed thrombolytic therapy did not reduce the incidence of post-thrombotic syndrome compared with conventional anticoagulant therapy. […] Consequently, thrombolytic agents should be considered only in highly selected patients with DVT.

• #42

  https://www.bostonscientific.com/en-US/patients-caregivers/device-support/peripheral-artery-vein-interventions/dvt.html

  Mechanical thrombectomy devices are special catheters designed to help break up and physically remove all or portions of the blood clot during a minimally invasive procedure. A mechanical thrombectomy procedure can help to quickly restore blood flow, reduce medication dosage, and may help prevent damage to the valves in your vein, which can cause post-thrombotic syndrome. […] […] These procedures come with risks and arent right for everyone. Be sure to talk to your doctor to find out if they may be right for you. […] […] Be sure to talk with your doctor so that you thoroughly understand all of the risks and benefits associated with treatment of Deep Vein Thrombosis.

• #43 Deep Vein Thrombosis (DVT) Symptoms & Treatment | University of Utah Health

  https://healthcare.utah.edu/thrombosis/dvt

  Thrombolytics This medicine will be administered through a catheter (a thin tube) in your vein to break up and dissolve the clot. […] Compression stockings These are high socks that fit tightly around your feet, legs, and thighs. Compression stockings will apply pressure and allow your blood to flow freely from the legs to the heart. The pressure will reduce pain and swelling and stop blood from clotting to form a DVT. […] If your doctor determines you need surgical intervention, our thrombosis specialists perform two types of procedures for patients with DVT. Surgery for DVT includes: […] Mechanical thrombectomy In this minimally invasive procedure, your doctor will use X-ray technology to guide a catheter through your vein to the clot. Your surgeon will then insert a stent retriever (looks similar to a net) into the clot, retrieve it, and pull it out. […] Suction thrombectomy During this procedure, your doctor will insert a catheter into the vein. Using a syringe, your doctor will suction the clot into the catheter and remove it from your body.

• #44 Effective DVT Treatment of Thrombectomy & Thrombolysis

  https://drakhilmonga.com/blog/effective-treatment-thrombectomy-and-thrombolysis/

  Thrombectomy is a minimally invasive procedure designed to remove blood clots from the blood vessels. It is typically performed in cases where the clot is large and causing significant obstruction or when the patient does not respond well to medication. This method involves inserting a catheter into the impacted vein, often through a small incision in the groin. The catheter is guided to the clot, where it either mechanically breaks up the clot or uses suction to remove it. […] Thrombolysis involves using drugs, known as thrombolytic agents, to dissolve blood clots. It is a less invasive option compared to thrombectomy and is often used for smaller clots. Thrombolysis can be administered in two ways: […] Pharmacomechanical thrombectomy is a minimally invasive procedure combining thrombectomy and thrombolysis to treat Deep Vein Thrombosis (DVT) without surgery. A catheter is inserted into the vein to mechanically break up the clot while delivering thrombolytic drugs directly to dissolve it. This method is effective for large clots, providing immediate relief with minimal surgical risks like infection or bleeding.

• #45 Deep Vein Thrombosis | Imaging & Radiology | Henry Ford Health – Detroit, MI

  https://www.henryford.com/services/imaging/services/interventional-radiology/deep-vein-thrombosis

  Deep vein thrombosis treatment includes several options such as catheter-directed thrombolysis, which involves infusing drugs over time to dissolve the thrombosis. […] Ekos or Trellis devices are used to break down the clot by utilizing the drug tPA (tissue plasminogen activator), ultrasound, or mechanically fragmenting the clot with a catheter. […] Balloon angioplasty and stenting involve inserting a balloon catheter into the narrowed or blocked vein, inflating the balloon to open the vein, and in some cases, inserting a stent to help keep the vein open. […] Interventional Radiologists are experts in the use of IVC filters to help prevent a DVT from traveling to the lungs and becoming a pulmonary embolism. […] Your particular deep vein thrombosis treatment will depend on the size of the clot, its location, and other factors. […] The NIH ATTRACT study sought to determine the most effective means of addressing venous clots in the legs and pelvis, with aggressive treatment aimed at avoiding post-thrombotic syndrome.

• #46 A Treatment Algorithm for DVT – Endovascular Today

  https://evtoday.com/articles/2014-july/a-treatment-algorithm-for-dvt

  Determining therapeutic protocol for acute and chronic DVT. […] There are ongoing clinical trials evaluating the effect of early intervention for acute DVT on the development of PTS, such as the NIH/NHLBI-sponsored ATTRACT trial and the recently enrolling ACCESS PTS trial, which looks at endovascular intervention for patients with documented PTS and the ability to recanalize diseased venous segments as well as reduce the sequelae of PTS. […] This article attempts to describe the basic algorithm for determining which type of DVT treatment a patient may receive and why. […] I consider standard catheter infusion of a thrombolytic agent after PMT for residual, acute thrombus. […] If there are no confounding factors, my standard approach to tackling acute and subacute DVT is to perform the rapid lysis technique, which we developed in 1997.

• #47 A Treatment Algorithm for DVT – Endovascular Today

  https://evtoday.com/articles/2014-july/a-treatment-algorithm-for-dvt

  This pharmacomechanical technique combines r-tPA with the AngioJet system, which is delivered through an 8-F hockey stick guide catheter coaxially placed through an 8-F sheath. […] This technique has allowed for a one-and-done treatment session in half of our patients without the need for catheter-directed thrombolysis (CDT). […] In patients with relative or even absolute contraindications to CDT, I will not withhold alteplase from the solution despite these bleeding risks, as it appears the majority of the thrombolytic agent is removed together with the thrombus and, theoretically, very little escapes into the systemic circulation. […] If there are any other medical concerns, aside from bleeding, contraindicating the use of the AngioJet system, then I typically use a CDT technique in an effort to prevent hemolysis and hemoglobinuria, which can further adversely affect renal function.

• #48 Deep vein thrombosis – Knowledge @ AMBOSS

  https://www.amboss.com/us/knowledge/deep-vein-thrombosis/

  Deep vein thrombosis (DVT) is the formation of a blood clot within the deep veins, most commonly those of the lower extremities. […] The initial test of choice for DVT is D-dimer in patients with a low PTP and venous ultrasound (US) in patients with moderate or high PTP. […] Long-term anticoagulation for 36 months is recommended in all patients with DVT, except for isolated asymptomatic distal DVT, for which expectant management with serial ultrasound may be considered, as the risk of postthrombotic sequelae is low. […] Prevention of recurrent DVT (i.e., anticoagulation extended indefinitely after completion of primary treatment) is recommended for select patients, depending on the extent and etiology of the DVT and the patient’s bleeding risk. […] Catheter-directed thrombolysis or thrombectomy may be considered for limb-threatening ischemia, acute iliofemoral DVT, and patients with contraindications to anticoagulation.

• #49 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  Use of direct oral anticoagulants (DOACs) are recommended as first-line treatment of acute DVT or PE. DOAC therapy is preferred over vitamin K antagonists (VKAs) for most patients without severe renal insufficiency (creatinine clearance). […] For most patients with proximal DVT, the ASH guidelines suggest anticoagulation therapy alone over thrombolytic therapy. Thrombolysis is reasonable to consider in patients presenting with limb-threatening DVT (phlegmasia cerulea dolens) or for select younger patients at low bleeding risk with iliofemoral DVT. […] For patients with acute PE and evidence of right ventricular dysfunction (by echocardiography and/or biomarkers), the ASH guidelines suggest anticoagulation alone over routine use of thrombolysis. Thrombolysis is reasonable to consider for patients at low bleeding risk who are at high risk for decompensation.

• #50 Deep vein thrombosis (DVT) – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/deep-vein-thrombosis/diagnosis-treatment/drc-20352563

  There are three main goals to DVT treatment. […] DVT treatment options include: […] Blood thinners. These medicines, also called anticoagulants, help prevent blood clots from getting bigger. Blood thinners reduce the risk of developing more clots. […] Clot busters (thrombolytics). These drugs are used for more-serious types of DVT or PE, or if other medications aren’t working. […] Filters. If you can’t take medicines to thin your blood, a filter may be placed into a large vein the vena cava in your belly (abdomen). A vena cava filter prevents clots that break loose from lodging in the lungs. […] Support stockings (compression stockings). These special knee socks help prevent blood from pooling in the legs. They help reduce leg swelling. Wear them on your legs from your feet to about the level of your knees. For DVT, you typically wear these stockings during the day for a few years, if possible.

• #51 Patient education: Deep vein thrombosis (DVT) (Beyond the Basics) – UpToDate

  https://www.uptodate.com/contents/deep-vein-thrombosis-dvt-beyond-the-basics

  Inferior vena cava filter—An inferior vena cava (IVC) filter is a device that blocks the circulation of clots in the bloodstream, especially the movement of a clot from the legs to the lungs. It is placed in the IVC (the large vein leading from the lower body to the heart). The IVC filter typically is inserted through a small incision in a leg vein with the use of a local anesthetic. An IVC filter may be recommended in people with venous thromboembolism who cannot use anticoagulants because of a very high bleeding risk. However, in the long term, IVC filters can actually increase the risk of developing blood clots.

• #52 Deep Vein Thrombosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK507708/

  Inferior vena cava filters: If anticoagulation is contraindicated or if emboli are occurring despite adequate anticoagulation. […] Rivaroxaban, apixaban, dabigatran, edoxaban, and betrixaban are relatively newer factor Xa inhibitors approved for prophylaxis of deep vein thrombosis. […] Inferior vena cava filters are not recommended in acute DVT. […] For patients with catheter-associated thrombosis, treatment consists of removing the catheter or anticoagulation if the catheter remains.

• #53 Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy | AAFP

  https://www.aafp.org/pubs/afp/issues/2017/0301/p295.html

  Guidelines recommend low-molecular-weight over unfractionated heparin, which is supported by multiple therapeutic trials showing greater effectiveness and safety and lower mortality. […] The ACCP recommends the use of direct-acting anticoagulants over warfarin for VTE treatment in patients without cancer (weak recommendation based on moderate quality evidence, per the ACCP grading system). […] For patients with recurrent VTE who are already taking an oral anticoagulant, low-molecular-weight heparin is recommended over other oral anticoagulants. […] For patients with recurrent VTE while taking a low-molecular-weight heparin, the dose should be increased by 25% to 33% (weak recommendations based on moderate to poor quality evidence per the ACCP grading system). […] If there is an absolute contraindication to therapeutic anticoagulation, complications from anticoagulation, or failure of anticoagulation in a patient with acute proximal DVT, an inferior vena cava filter may be indicated. […] Long-term anticoagulation reduces the risk of recurrent VTE but results in more bleeding events. Considering this trade-off, it is critical that the duration of anticoagulation therapy be individualized based on the patient’s risk of recurrence vs. risk of bleeding.

• #54 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  For patients with extensive DVT in whom thrombolysis is considered appropriate, the ASH guidelines suggest using catheter-directed thrombolysis over systemic thrombolysis. In contrast, for patients with acute PE in whom thrombolysis is considered appropriate, the ASH guidelines suggest using systemic thrombolysis over catheter-directed thrombolysis partially due to a paucity of randomized trial data. […] For patients with proximal DVT and significant pre-existing cardiopulmonary disease as well as patients with PE and hemodynamic compromise, the ASH guidelines suggest anticoagulation alone over anticoagulation plus inferior vena cava (IVC) filter placement. The use of retrievable IVC filters is appropriate for patients with a contraindication to anticoagulation. […] The ASH guidelines define the treatment period of acute DVT/PE as initial management (first 5-21 days), primary treatment (first 3-6 months), and secondary prevention (beyond the first 3-6 months). The guidelines favor shorter courses of anticoagulation (3-6 months) for acute DVT/PE associated with a transient risk factor. The guidelines suggest indefinite anticoagulation for most patients with unprovoked DVT/PE or a DVT/PE associated with a chronic risk factor.

• #55 Deep Venous Thrombosis (DVT) Treatment & Management: Approach Considerations, General Principles of Anticoagulation, Heparin Use in Deep Venous Thrombosis

  https://emedicine.medscape.com/article/1911303-treatment

  If DVT recurs, if a chronic hypercoagulability is identified, or if the PE is life-threatening, lifetime anticoagulation therapy may be recommended. […] Anticoagulant therapy remains the mainstay of medical therapy for deep venous thrombosis (DVT) because it is noninvasive, it treats most patients (approximately 90%) with no immediate demonstrable physical sequelae of DVT, it has a low risk of complications, and its outcome data demonstrate an improvement in morbidity and mortality. […] First-line therapy for non-high risk venous thromboembolism (VTE) or pulmonary embolism (PE) consists of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, or edoxaban) over vitamin K antagonists (VKAs). […] Inferior vena cava filters are not recommended in patients with acute VTE on anticoagulant therapy.

• #56 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  For patients with extensive DVT in whom thrombolysis is considered appropriate, the ASH guidelines suggest using catheter-directed thrombolysis over systemic thrombolysis. In contrast, for patients with acute PE in whom thrombolysis is considered appropriate, the ASH guidelines suggest using systemic thrombolysis over catheter-directed thrombolysis partially due to a paucity of randomized trial data. […] For patients with proximal DVT and significant pre-existing cardiopulmonary disease as well as patients with PE and hemodynamic compromise, the ASH guidelines suggest anticoagulation alone over anticoagulation plus inferior vena cava (IVC) filter placement. The use of retrievable IVC filters is appropriate for patients with a contraindication to anticoagulation. […] The ASH guidelines define the treatment period of acute DVT/PE as initial management (first 5-21 days), primary treatment (first 3-6 months), and secondary prevention (beyond the first 3-6 months). The guidelines favor shorter courses of anticoagulation (3-6 months) for acute DVT/PE associated with a transient risk factor. The guidelines suggest indefinite anticoagulation for most patients with unprovoked DVT/PE or a DVT/PE associated with a chronic risk factor.

• #57 Interventional Therapies to Treat Blood Clots and Their Complications – Blood Clots

  https://www.stoptheclot.org/interventional-therapies/

  In addition, a physician may sometimes use other clot removal treatments, with or without the use of thrombolytic or clot-busting therapy, including: Mechanical thrombectomy (clot removal) devices to mechanically break up the clot into smaller pieces and remove the clot pieces. […] Angioplasty and stents also can be used to treat people with a chronic or older DVT and severe PTS. […] For people diagnosed with a DVT who are unable to take anticoagulation therapies, a filter may be placed into the inferior vena cava (IVC), which is the large vein that carries deoxygenated blood from the lower and middle body into the heart. […] However, experts advise that filters not be routinely used among people who can receive anticoagulation therapy, because the use of filters can cause new clots to form.

• #58 Deep vein thrombosis (DVT) – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/deep-vein-thrombosis/diagnosis-treatment/drc-20352563

  There are three main goals to DVT treatment. […] DVT treatment options include: […] Blood thinners. These medicines, also called anticoagulants, help prevent blood clots from getting bigger. Blood thinners reduce the risk of developing more clots. […] Clot busters (thrombolytics). These drugs are used for more-serious types of DVT or PE, or if other medications aren’t working. […] Filters. If you can’t take medicines to thin your blood, a filter may be placed into a large vein the vena cava in your belly (abdomen). A vena cava filter prevents clots that break loose from lodging in the lungs. […] Support stockings (compression stockings). These special knee socks help prevent blood from pooling in the legs. They help reduce leg swelling. Wear them on your legs from your feet to about the level of your knees. For DVT, you typically wear these stockings during the day for a few years, if possible.

• #59 Deep Vein Thrombosis (DVT)

  https://my.clevelandclinic.org/health/diseases/16911-deep-vein-thrombosis-dvt

  Deep vein thrombosis is a blood clot in a vein located deep within your body, usually in your leg. Get treatment right away so you can prevent serious complications. Treatments include medicines, compression stockings and surgery. Be patient. You may need to take medicine for a few months and wear compression stockings for two years. […] Treatments include medications called anticoagulants (blood thinners), compression stockings and elevating your affected leg(s) at different times throughout the day. In a minority of cases, when the DVT is extensive, invasive treatments (catheter-based procedures) may be required. […] The main goals of treatment are to: Keep the clot from getting bigger and involving other veins. Prevent the clot from breaking off in your vein and moving to your lungs. Lessen the risk of another blood clot. Prevent long-term complications from the blood clot (like chronic venous insufficiency).

• #60 Deep Vein Thrombosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK507708/

  In circumstances where once-daily oral therapy is the preferred management, the following options are viable; 1. rivaroxaban, 2. edoxaban, and 3. vitamin-K antagonist (VKA). […] Moreover, the following guidelines address the required duration of treatment. […] Prescribe low-molecular-weight heparin or fondaparinux for 5 days or until the international normalized ratio (INR) is greater than 2 for 24 hours (unfractionated heparin for patients with renal failure and increased risk of bleeding). […] If thrombolytic therapy is indicated, unfractionated heparin is indicated. […] The use of thrombolytic therapy can result in an intracranial bleed, and hence, careful patient selection is vital. […] Compression hosiery: Below-knee graduated compression stockings with an ankle pressure greater than 23 mm Hg for 2 years if there are no contraindications.

• #61 Deep Venous Thrombosis (DVT) Treatment & Management: Approach Considerations, General Principles of Anticoagulation, Heparin Use in Deep Venous Thrombosis

  https://emedicine.medscape.com/article/1911303-treatment

  The addition of percutaneous mechanical thrombectomy to the interventional options may facilitate decision making, because recanalization may be achieved faster than before and with a decreased dose of thrombolytics; therefore, the bleeding risk may be decreased. […] The regular use of graduated elastic compression stockings reduced the incidence of PTS by 50%. […] The authors strongly recommended the early use and widespread implementation of graduated elastic stockings with adequate anticoagulant therapy for symptomatic proximal DVT to prevent the development of PTS.

• #62 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  The ASH guidelines suggest against the routine use of prognostic scores, D-dimer testing, or venous ultrasound to guide the duration of anticoagulation. […] For patients with breakthrough DVT and/or PE while on therapeutic VKA treatment, the ASH guidelines suggest using low molecular weight heparin over DOAC therapy. This does not apply to patients who experience breakthrough DVT/PE due to poor international normalized ratio control. […] For patients with DVT/PE with stable cardiovascular disease, the ASH guidelines suggest suspending aspirin therapy when initiating anticoagulation. The combination of anticoagulation plus aspirin increases the risk of bleeding without clear evidence of benefit for patients with stable cardiovascular disease. […] For patients with acute DVT who are not at high risk for post-thrombotic syndrome, the ASH guidelines recommend against the routine use of compression stockings. However, select patients may benefit from compression stockings to help with edema and pain associated with acute DVT.

• #63 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  The ASH guidelines suggest against the routine use of prognostic scores, D-dimer testing, or venous ultrasound to guide the duration of anticoagulation. […] For patients with breakthrough DVT and/or PE while on therapeutic VKA treatment, the ASH guidelines suggest using low molecular weight heparin over DOAC therapy. This does not apply to patients who experience breakthrough DVT/PE due to poor international normalized ratio control. […] For patients with DVT/PE with stable cardiovascular disease, the ASH guidelines suggest suspending aspirin therapy when initiating anticoagulation. The combination of anticoagulation plus aspirin increases the risk of bleeding without clear evidence of benefit for patients with stable cardiovascular disease. […] For patients with acute DVT who are not at high risk for post-thrombotic syndrome, the ASH guidelines recommend against the routine use of compression stockings. However, select patients may benefit from compression stockings to help with edema and pain associated with acute DVT.

• #64 Interventional Therapies to Treat Blood Clots and Their Complications – Blood Clots

  https://www.stoptheclot.org/interventional-therapies/

  In addition, a physician may sometimes use other clot removal treatments, with or without the use of thrombolytic or clot-busting therapy, including: Mechanical thrombectomy (clot removal) devices to mechanically break up the clot into smaller pieces and remove the clot pieces. […] Angioplasty and stents also can be used to treat people with a chronic or older DVT and severe PTS. […] For people diagnosed with a DVT who are unable to take anticoagulation therapies, a filter may be placed into the inferior vena cava (IVC), which is the large vein that carries deoxygenated blood from the lower and middle body into the heart. […] However, experts advise that filters not be routinely used among people who can receive anticoagulation therapy, because the use of filters can cause new clots to form.

• #65 Deep Vein Thrombosis (DVT) – UChicago Medicine

  https://www.uchicagomedicine.org/conditions-services/heart-vascular/thrombosis-and-embolism/deep-vein-thrombosis

  If clot-busting medication and anticoagulants are not enough to dissolve or decrease the blood clot, or if you cannot take these medications, IVC filters can be implanted in the vein to trap blood clots if they were to embolize. […] This minimally invasive procedure uses image-guided technology to insert a small catheter into the blood vessel and deliver targeted medication directly into the blood clot. […] Through catheterization, a small, thin tube (catheter) is placed into the vessel near the thrombus. With image-guided technology, the catheter is then used to break up and remove the thrombus. […] When vessels such as the iliac veins or the inferior vena cava are blocked from clot for a long time, the vein may ultimately scar. In these circumstances, radiologists or surgeons may perform a procedure known as recanalization to create a new channel or path in the vessel to restore blood flow. This procedure is typically done minimally invasively using image-guided technology.

• #66

  https://www.bostonscientific.com/en-US/patients-caregivers/device-support/peripheral-artery-vein-interventions/dvt.html

  Many DVT blood clots will be absorbed by your body over time with the help of blood thinners. But in the meantime, the clot can cause permanent damage to the valves in your vein, resulting in a condition known as post-thrombotic syndrome (PTS), which causes chronic pain and swelling. Mechanical thrombectomy and IV clot busters may help reduce your risk of developing PTS. […] […] Procedures to treat DVT include: […] […] The Venous Wallstent self-expanding stent is a small, flexible tube specifically designed to hold open the narrowed vein that is partially or completely blocked. […] […] IV clot busters, or thrombolytics, are medications placed directly into the clot during a minimally invasive procedure. Theyre designed to quickly dissolve clots, restore blood flow, and may help prevent damage to the valves in your vein, which can cause post-thrombotic syndrome. […]

• #67 Effective DVT Treatment of Thrombectomy & Thrombolysis

  https://drakhilmonga.com/blog/effective-treatment-thrombectomy-and-thrombolysis/

  For patients with May-Thurner Syndrome, where the left iliac vein is compressed, stenting may be required to keep the vein open after clot removal, preventing the recurrence of DVT and improving blood flow. This combination of pharmacomechanical thrombectomy with stenting can be highly effective in maintaining long-term vein health. […] Post-treatment care is crucial to ensure recovery and prevent recurrence. This typically includes: […] Deep Vein Thrombosis is a severe illness that requires prompt attention. Understanding the risks, recognising the symptoms, and seeking timely treatment can significantly improve outcomes. All the above procedures are effective treatment options, each with its benefits. By following preventive measures and post-treatment care, the risk of recurrence can be minimised.

• #68 Deep Vein Thrombosis | Imaging & Radiology | Henry Ford Health – Detroit, MI

  https://www.henryford.com/services/imaging/services/interventional-radiology/deep-vein-thrombosis

  Deep vein thrombosis treatment includes several options such as catheter-directed thrombolysis, which involves infusing drugs over time to dissolve the thrombosis. […] Ekos or Trellis devices are used to break down the clot by utilizing the drug tPA (tissue plasminogen activator), ultrasound, or mechanically fragmenting the clot with a catheter. […] Balloon angioplasty and stenting involve inserting a balloon catheter into the narrowed or blocked vein, inflating the balloon to open the vein, and in some cases, inserting a stent to help keep the vein open. […] Interventional Radiologists are experts in the use of IVC filters to help prevent a DVT from traveling to the lungs and becoming a pulmonary embolism. […] Your particular deep vein thrombosis treatment will depend on the size of the clot, its location, and other factors. […] The NIH ATTRACT study sought to determine the most effective means of addressing venous clots in the legs and pelvis, with aggressive treatment aimed at avoiding post-thrombotic syndrome.

• #69 Deep Vein Thrombosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK507708/

  A deep-vein thrombosis (DVT) is a blood clot that forms within the deep veins, usually of the leg, but can occur in the arms and the mesenteric and cerebral veins. […] This activity reviews the etiology, presentation, evaluation, and management of deep vein thrombosis and reviews the role of the interprofessional team in evaluating, diagnosing, and managing the condition. […] Summarize the treatment and management strategies for deep vein thrombosis, including preventative measures. […] Treatment of DVT aims to prevent pulmonary embolism, reduce morbidity, and prevent or minimize the risk of developing post-thrombotic syndrome. The cornerstone of treatment is anticoagulation. […] Treatment for DVT should be addressed mainly according to the underlying causality of DVT as follows: […] The preferred anticoagulant to address DVT in cancer-associated thromboembolism is low molecular weight heparin and factor Xa inhibitors, including rivaroxaban.

• #70 Medications for Deep Venous Thrombosis – Cardiovascular Disorders – MSD Manual Professional Edition

  https://www.msdmanuals.com/professional/cardiovascular-disorders/peripheral-venous-disorders/medications-for-deep-venous-thrombosis

  The main disadvantage is the higher cost compared to warfarin and the high cost of DOAC reversal agents in the case of bleeding or need for an urgent surgery or procedure. […] Duration of treatment varies. Patients with transient risk factors for DVT can usually stop taking anticoagulants after 3 to 6 months. Patients with idiopathic DVT with no known risk factors, or recurrent DVT should take anticoagulants for at least 6 months and, in selected patients, probably for life unless they are at high risk for bleeding complications. […] A low molecular weight heparin is one of the initial treatments of choice because LMWHs can be given on an outpatient basis. […] LMWHs and direct oral anticoagulants are first-line treatment options for patients with cancer-associated DVT. […] Unfractionated heparin may be used instead of LMWH for patients who are hospitalized and for patients who have renal insufficiency or failure.

• #71 DVT (deep vein thrombosis)

  https://www.nhs.uk/conditions/deep-vein-thrombosis-dvt/

  You may have an injection of a blood-thinning medicine called heparin while you’re waiting for an ultrasound scan to see if you have a DVT (deep vein thrombosis). […] The main treatments include: blood-thinning medicines, such as warfarin or rivaroxaban you’ll probably need to take these for at least 3 months […] surgery to remove blood clots or stop them forming. […] If you get a DVT when you’re pregnant, you’ll have injections for the rest of the pregnancy and until your baby is 6 weeks old.

• #72 Diagnosis and treatment of deep-vein thrombosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC1609160/

  For the majority of patients with DVT, oral therapy with vitamin K antagonists (e.g., warfarin) is very effective for long-term prevention of recurrent thrombosis. […] The risk can be classified into the following 5 categories: First proximal DVT occurs in the context of a transient risk factor (e.g., surgery or trauma). […] After a second recurrence of DVT, the risk of further thromboembolic events following the discontinuation of anticoagulation therapy is felt to be excessive if only 6 months of oral anticoagulation therapy is administered. […] The standard intensity of oral anticoagulation therapy is an international normalized ratio (INR) of 2 to 3. […] Although anticoagulation therapy is the mainstay of treatment of DVT, thrombolysis and placement of an inferior vena cava filter are 2 interventions that deserve mention. […] LMW heparin is the treatment of choice for DVT during pregnancy.

• #73 Deep vein thrombosis

  https://www2.hse.ie/conditions/deep-vein-thrombosis/

  If you are diagnosed with DVT you will continue with heparin injections. […] Heparin is given under the skin once a day for 4 to 5 days. You will usually be switched to a tablet form of medication after this. […] Warfarin used to be the standard medication for DVT. Newer anticoagulant medications called direct oral anti-coagulation (DOAC) are now being used. These are also known as 'novel’ or 'newer’ oral anti-coagulation (NOAC). How long you have to take this medication will depend on the cause of the DVT and how serious it is. […] In rare cases where a leg is in danger, the clot may be dissolved using clot-busting drugs. […] DVT in pregnancy is treated with anticoagulant injections for the rest of the pregnancy and until the baby is at least 6 weeks old.

• #74 Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy | AAFP

  https://www.aafp.org/pubs/afp/issues/2017/0301/p295.html

  Symptomatic distal deep venous thrombosis should be treated with anticoagulation, but asymptomatic patients may be monitored with serial imaging for two weeks and treated only if there is extension. […] Anticoagulation is not recommended for isolated distal DVTs (i.e., confined to calf veins) unless the patient is symptomatic, has risk factors for extension (e.g., unprovoked DVT, prior VTE), or develops extension of DVT on serial imaging for two weeks. […] Evidence supports outpatient treatment of PE if the risk of nonadherence is low and the patient is clinically stable; has no contraindications to anticoagulation, such as recent bleeding, severe renal or liver disease, or platelet count of less than 70 103 per mm3 (70 109 per L); and feels capable of managing the disease at home. […] If warfarin is selected, concomitant parenteral anticoagulation is required for at least five days; if dabigatran (Pradaxa) or edoxaban (Savaysa) is selected they should be initiated after five to 10 days of initial therapy with a parenteral anticoagulant.

• #75 Deep vein thrombosis – Knowledge @ AMBOSS

  https://www.amboss.com/us/knowledge/deep-vein-thrombosis/

  Deep vein thrombosis (DVT) is the formation of a blood clot within the deep veins, most commonly those of the lower extremities. […] The initial test of choice for DVT is D-dimer in patients with a low PTP and venous ultrasound (US) in patients with moderate or high PTP. […] Long-term anticoagulation for 36 months is recommended in all patients with DVT, except for isolated asymptomatic distal DVT, for which expectant management with serial ultrasound may be considered, as the risk of postthrombotic sequelae is low. […] Prevention of recurrent DVT (i.e., anticoagulation extended indefinitely after completion of primary treatment) is recommended for select patients, depending on the extent and etiology of the DVT and the patient’s bleeding risk. […] Catheter-directed thrombolysis or thrombectomy may be considered for limb-threatening ischemia, acute iliofemoral DVT, and patients with contraindications to anticoagulation.

• #76 Treatment of Distal DVT | AAFP

  https://www.aafp.org/pubs/afp/issues/2021/0401/p432.html

  Study Population: Adults with distal deep venous thrombosis (DVT) diagnosed using venography or ultrasonography […] The standard treatments for distal DVT include anticoagulation or close observation with repeat evaluations to monitor for potential progression of the thrombosis, most significantly extension above the knee. […] The American College of Chest Physicians (CHEST) recommends anticoagulation if risk factors for DVT extension are present (weak recommendation with low-quality evidence). […] If no risk factors are present, CHEST recommends observation (weak recommendation with low-quality evidence). In patients at high risk of bleeding, observation is preferred. […] The Cochrane review demonstrated that anticoagulation was effective and superior to observation; however, given the limited number of patients, potential biases, and conflicting recommendations from CHEST, we give this treatment a yellow rating (unclear benefits). Further studies, specifically larger randomized controlled trials, are needed to confirm the best treatment for distal DVT.

• #77 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  The following are key points to remember from the American Society of Hematology (ASH) 2020 guidelines for the management of venous thromboembolism (VTE): treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE): […] The ASH guidelines suggest home treatment over hospitalization for patients with uncomplicated acute DVT. This does not apply to patients who have other reasons for hospitalization, who lack support at home, who cannot afford medications, or who present with limb-threatening DVT or at high risk for bleeding. […] The ASH guidelines suggest offering home treatment instead of hospitalization for patients with acute PE at low risk for complications. This includes patients at low risk based on the Pulmonary Embolism Severity Index (PESI) or its simplified version. Patients with submassive (intermediate-high risk) or massive PE as well as patients at high risk for bleeding may benefit from hospitalization.

• #78 Health Care Providers (HCPs) – Addressing the Patient with Suspected DVT – The Society for Vascular Medicine

  https://mydeepveinthrombosis.com/addressing-the-patient-with-suspected-dvt/

  Many patients with acute deep venous thrombosis (DVT) can be safely and effectively treated without the need for emergency department visit. […] Most patients can be treated with a single drug therapy approach, thus avoiding unnecessary complexity and expense of two drugs. This can be done either using apixaban or rivaroxaban, as noted below. […] Other patients can be treated initially with low molecular weight heparin (LMWH) and then transitioned either to warfarin or one of two direct oral anticoagulants (dabigatran or edoxaban). […] It is important to check the renal function of all patients prior to initiating therapy. LMWH and all of the direct oral anticoagulants must be dose-adjusted or avoided in patients with chronic kidney disease. […] If the DVT scan is negative, then clinical follow up is important. If, however, the DVT scan is positive, then initiating treatment acutely is important. Options include two drug strategies that start with low molecular weight heparin (LMWH) or fondaparinux and then transition either to warfarin or to a newer direct oral anticoagulant (e.g., dabigatran or edoxaban). However, many patients prefer a one-drug approach, with either rivaroxaban or apixaban.

• #79 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  Use of direct oral anticoagulants (DOACs) are recommended as first-line treatment of acute DVT or PE. DOAC therapy is preferred over vitamin K antagonists (VKAs) for most patients without severe renal insufficiency (creatinine clearance). […] For most patients with proximal DVT, the ASH guidelines suggest anticoagulation therapy alone over thrombolytic therapy. Thrombolysis is reasonable to consider in patients presenting with limb-threatening DVT (phlegmasia cerulea dolens) or for select younger patients at low bleeding risk with iliofemoral DVT. […] For patients with acute PE and evidence of right ventricular dysfunction (by echocardiography and/or biomarkers), the ASH guidelines suggest anticoagulation alone over routine use of thrombolysis. Thrombolysis is reasonable to consider for patients at low bleeding risk who are at high risk for decompensation.

• #80 ASH Venous Thromboembolism Guidelines: Treatment of DVT and PE

  https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/10/08/15/01/American-Society-of-Hematology-2020-Guidelines

  For patients with extensive DVT in whom thrombolysis is considered appropriate, the ASH guidelines suggest using catheter-directed thrombolysis over systemic thrombolysis. In contrast, for patients with acute PE in whom thrombolysis is considered appropriate, the ASH guidelines suggest using systemic thrombolysis over catheter-directed thrombolysis partially due to a paucity of randomized trial data. […] For patients with proximal DVT and significant pre-existing cardiopulmonary disease as well as patients with PE and hemodynamic compromise, the ASH guidelines suggest anticoagulation alone over anticoagulation plus inferior vena cava (IVC) filter placement. The use of retrievable IVC filters is appropriate for patients with a contraindication to anticoagulation. […] The ASH guidelines define the treatment period of acute DVT/PE as initial management (first 5-21 days), primary treatment (first 3-6 months), and secondary prevention (beyond the first 3-6 months). The guidelines favor shorter courses of anticoagulation (3-6 months) for acute DVT/PE associated with a transient risk factor. The guidelines suggest indefinite anticoagulation for most patients with unprovoked DVT/PE or a DVT/PE associated with a chronic risk factor.

• #81 Management of lower-extremity venous thromboembolism: An updated review | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/91/4/229

  The 2021 CHEST guidelines recommend treating proximal DVT with anticoagulation for at least 3 months. […] Proximal DVT confers up to a 50% risk of pulmonary embolism if left untreated, so treatment with anticoagulation is recommended even in the absence of symptoms (incidental DVT). […] The 2021 CHEST guidelines recommend the use of DOACs over warfarin whenever possible, based on data showing a lower risk of major bleeding (especially intracranial hemorrhage) with DOACs vs warfarin. […] The 2021 CHEST guidelines recommend fondaparinux as the agent of choice for the treatment of SVT, but rivaroxaban is an acceptable alternative. […] When anticoagulation is indicated in patients with DVT, treatment should continue for at least 3 months after the initial thrombotic episode. […] Anticoagulation beyond 3 months, without a specific end date, is recommended for patients at particularly high risk of recurrence.

• #82 Anticoagulation in Deep Venous Thrombosis: Advantages of Anticoagulant Therapy, Initial Anticoagulation Therapy, Long-Term Anticoagulation

  https://emedicine.medscape.com/article/1926110-overview

  The American Society of Hematology (ASH) released their updated recommendations on the management of venous thromboembolism (VTE) (deep vein thrombosis [DVT] and pulmonary embolism [PE]) in October 2020. […] For patients with PE and hemodynamic compromise, it is recommended that thrombolytic therapy followed by anticoagulation be used over anticoagulation alone. […] For patients with DVT and/or PE who have completed primary treatment and will continue vitamin K antagonist (VKA) therapy as secondary prevention, it is recommended that an international normalized ratio (INR) range of 2.0 to 3.0 be used over a lower INR range (eg, 1.5-1.9). […] For patients with a recurrent unprovoked DVT and/or PE, indefinite antithrombotic therapy is recommended over stopping anticoagulation after completion of primary treatment.

• #83 Effective Treatment Options for Deep Vein Thrombosis (DVT)

  https://flowcare.co.in/deep-vein-thrombosis-treatment/

  Minimally invasive treatment options like catheter-directed thrombolysis have demonstrated promising results in DVT treatment, with a high success rate and minimal risk of complications. Discussing these options with a doctor can help determine their suitability for individual cases. […] In conclusion, deep vein thrombosis is a severe medical condition that requires immediate treatment to prevent serious health complications. If any signs or symptoms of DVT are experienced, it is essential to consult a doctor promptly. Treatment options include anticoagulant medications, compression stockings, and interventional radiology procedures such as catheter-directed thrombolysis or the placement of an IVC filter. Doctors work closely with patients to develop personalized treatment plans based on their specific needs and goals.

Zobacz więcej